Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
复制标题
DOI:
10.1158/1078-0432.ccr-08-2319
复制
发表时间:
2009-05-01
期刊:
影响因子:
--
通讯作者:
Hwang ES
中科院分区:
文献类型:
--
作者:
Suzuki J;Chen YY;Scott GK;Devries S;Chin K;Benz CC;Waldman FM;Hwang ES
Excess histone deacetylase (HDAC) activity can induce hypoacetylation of histone and non-histone protein substrates, altering gene expression patterns and cell behavior potentially associated with malignant transformation. However, HDAC expression and protein acetylation have not been studied in the context of breast cancer progression. We performed immunohistochemistry (IHC) to assess expression levels of acetylated histone H4 (ac-H4), ac-H4K12, ac-tubulin, HDAC1, HDAC2 and HDAC6 in 58 breast specimens with synchronous normal epithelium (N), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) components. Differences in IHC scoring between groups were tested for significance using non-parametric tests. From N to DCIS, there was marked reduction in histone acetylation (p<0.0001). Most cases showed similar levels of acetylation in DCIS and IDC, although some showed further reduction of ac-H4 and ac-H4K12 from DCIS to IDC. Expression of HDACs 1, 2, and 6 were also significantly reduced but by a smaller magnitude. Greater reductions of H4 acetylation and HDAC1 levels were observed from N to DCIS in ER-negative compared to ER-positive, and in high grade tumors compared to non-high grade tumors. Overall, there was a global pattern of hypoacetylation associated with progression from N to DCIS to IDC. Paradoxically, this was associated with reduction in HDAC expression levels, suggesting that this hypoacetylation pattern reflects a change in the balance between HDAC and histone acetyltransferase (HAT) catalytic activities. These findings also suggest that the reversal of this hypoacetylation in DCIS and IDC could be an early measure of HDAC inhibitor activity.